Cinda Bio and MD Anderson Cancer Center Announce Strategic Partnership

REVIEW: joint development of PD-1 inhibitors for the treatment of various cancers Dabo Shutoday, Cinda biopharmaceutical announcement said the United States and the University of Texas MD Anderson Cancer Center conducted jointly announced a strategic partnership, the two sides will jointly develop anti-PD in the United States Da Boshu 1 monoclonal antibody (mAb channel Dealy injection) for the treatment of a variety of rare cancersletter Dealey monoclonal antibody is an effective immune checkpoint inhibitors, through this partnership, the two sides will jointly promote their research for the treatment of rare cancersRelying on a wealth of MD Anderson Cancer Center in the field of rare cancer clinical trial experience, the letter Dealey monoclonal rare cancer indications is expected to get more of the US Food and Drug Administration approvalIn addition, the letter will also be solely responsible for biological monoclonal antibody Dealey letter listing application work of other high incidence of cancer indicationsUnder the agreement, the letter of biological and MD Anderson Cancer Center will share development costs Dealey letter monoclonal antibody, which may include a number of clinical studies conducted by MD Anderson Cancer Centerabout Dabo Shu (letter Dealey monoclonal antibody injection)Dabo Shu (letter Dealey monoclonal antibody injection) is a biopharmaceutical Cinda Eli Lilly and international co-operation in China R & D quality innovative biological medicineThe first of its approved indication is relapsed / refractory classical Hodgkin's lymphoma, and selected version of the 2019 Chinese Society of Clinical Oncology (CSCO) lymphoma treatment guidelines2019 Medicare talk about countries, Dabo Shu (letter Dealey monoclonal antibody injection) is the only access to the national health insurance of PD-1 inhibitorsIn April 2020, NMPA formally accepted Dabo Shu (letter Dealey monoclonal antibody injection) joint Alimta (pemetrexed for injection disodium) and platinum-based chemotherapy in first-line treatment of non-squamous non-small cell lung cancer new indications Application2020 May, Phase III studies Dabo Shu (letter Dealey monoclonal antibody injection) joint Gemzar ® (gemcitabine for injection) and platinum-based chemotherapy first-line treatment of squamous non-small cell lung cancer reaches primary endpoint, Dabo Shu ORIENT-2 study (mAb injection channel Dealy) monotherapy second-line treatment of advanced / metastatic esophageal squamous cell carcinoma has reached the primary endpointDa Boshu (Chantilly channel mAb injection) is a human immunoglobulin G4 (IgG4) a monoclonal antibody that specifically binds a T cell surface PD-1 molecule, thereby resulting in blocking tumor immunity tolerance PD-1 / programmed death receptor ligand 1 (programmed death-ligand 1, PD-L1) pathway, reactivate antitumor activity of lymphocytes, so as to achieve the purpose of treatment of tumorThere are currently more than 20 clinical studies (of which more than 10 are registered clinical trials) underway to evaluate the anti-tumor effects letter Dealey monoclonal antibody in various solid tumors and hematological malignanciesCinda is the world's biological clinical research while working channel Dealey monoclonal antibody injectionMD Anderson Cancer CenterUniversity of Texas in Houston, USA, is one of the world's leading cancer centers, is dedicated to providing care, research, education and prevention for cancer patientsThe only mission of the agency is the end of cancer patients and their families around the worldMD Anderson Cancer Center is one of 51 Comprehensive Cancer Center National Cancer Institute (NCI) designatedIn the "US News And World Report" and "Best Hospitals" survey, MD Anderson Cancer Center ranked first in cancer careSince the survey carried out in 1990, MD Anderson Cancer Center among the top two in each year of the nation's cancer care hospital, was ranked first 15 times in the past 18 yearsMD Anderson Cancer Center by the US National Institutes of Health NCI's Cancer Center Support grant (P30 CA016672)a Editor: MengmengRelated tags:U.S, letter biological, Anderson Cancer Center< br /> 00